We recently published 10 Big Names Leaving Wall Street in the Dust; 4 at Fresh Highs. ImmunityBio Inc. (NASDAQ:IBRX) is one ...

London: GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Investing.com -- ImmunityBio (NASDAQ:IBRX) stock rose 3.9% Friday after the European Medicines Agency (EMA) recommended granting conditional marketing authorization for its bladder cancer therapy ...

As per previous communication, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had informed Anavex about a negative trend-vote following its oral examination in ...

Just in December, six companies have announced the launch of their denosumab biosimilars in Europe: Sandoz, Samsung Bioepis, Fresenius Kabi, ...

Ultra-long-acting treatment could reshape respiratory care as EU regulators back GSK's high-stakes depemokimab ahead of 2026 ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting ...

EMA recommends conditional authorization for ImmunityBio's Anktiva with BCG after a 71% complete response rate in ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...